A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Recruiting · Phase 4 · NCT06145373
Conditions: Hemophilia A
At a glance
- Research payments reported, 2025
- $24,955
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Sanofi
- Tested
- Fitusiran (SAR439774) (drug), Clotting factor concentrates (CFC) or bypassing agents (BPA) (biological), Antithrombin concentrate (ATIIIC) (biological), Emicizumab (biological)
- Dates
- Started 2024-03-01; completion 2030-01-30
- Results posted
- Not yet
This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis. This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study will be conducted in male participants with severe hemophilia A, with or without inhibitors, aged ≥12 years, who were previously receiving emicizumab prophylaxis. Study details include: * The study duration will be up to approximately 28 months: * There will be an approximately 2-month screening period. * There will be an approximately 2-month period before fitusiran treatment starts (pre-fitu…
From ClinicalTrials.gov, last updated 2026-09-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $24,955 in research payments for this study in 2025 (3 payments).
Products named: Qfitlia
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.